Obese Patients with Chronic-Phase CML Experience Delayed Responses and Lower Response Rates to First-Line Imatinib

Share this content:

(ChemotherapyAdvisor) – Elevated body mass index (BMI > 25), a suspected risk factor for chronic myeloid leukemia (CML), is also associated with delayed cytogenetic and major molecular responses among patients treated with imatinib for chronic phase (CP) CML, report authors of a study published online in Cancer Letters.

“The results suggest that CML patients with increased weight at baseline should be followed and closely monitored if treated with standard-dose imatinib front-line for a possible early switch” to nilotinib or dose optimization, reported lead author Massimo Breccia, MD, of the Department of Cellular Biotechnologies and Hematology, Sapienza University, in Rome, Italy, and coauthors.

The authors studied clinical responses to targeted therapies among 339 patients with chronic phase (CP) CML, who were treated with imatinib, and 35 patients with CP-CML who were treated with first-line nilotinib.

Compared to patients with low BMIs (<18.5), patients with increased BMI at diagnosis who received imatinib “showed a significantly longer median time to achieve complete cytogenetic response (6.8 months vs. 3.3 months; P=0.001), and a reduced rate of major molecular response (77% vs. 58%; P=0.01), which was also achieved in a longer median time (29 months vs. 14 months, P=0.01),” the authors reported.

Conversely, they noted that “no differences were revealed with respect to BMI in patients treated front-line with nilotinib,” and that patients with increased BMI acheived rapid CCyR (complete cytogenic response) and MMR (major molecular response) at a rate similar to that of patients who were underweight/normal-weight.

Dr. Breccia disclosed receiving honoraria from Novartis, which markets nilotinib as Tasigna.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs